(NASDAQ: RNXT) Renovorx's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 44.75%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.88%.
Renovorx's earnings in 2025 is -$11,105,000.On average, 6 Wall Street analysts forecast RNXT's earnings for 2025 to be -$11,962,533, with the lowest RNXT earnings forecast at -$11,852,583, and the highest RNXT earnings forecast at -$11,929,548. On average, 6 Wall Street analysts forecast RNXT's earnings for 2026 to be -$13,084,020, with the lowest RNXT earnings forecast at -$22,627,658, and the highest RNXT earnings forecast at -$7,696,482.
In 2027, RNXT is forecast to generate -$1,869,146 in earnings, with the lowest earnings forecast at -$5,387,538 and the highest earnings forecast at $1,924,121.